VBIZF (Viva Biotech Holdings) 3-Year Revenue Growth Rate : 30.20% (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Viva Biotech Holdings 3-Year Revenue Growth Rate?

Viva Biotech Holdings's Revenue per Share for the six months ended in Jun. 2024 was $0.06.

During the past 12 months, Viva Biotech Holdings's average Revenue per Share Growth Rate was -27.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was 30.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 58.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 9 years, the highest 3-Year average Revenue per Share Growth Rate of Viva Biotech Holdings was 101.80% per year. The lowest was 30.20% per year. And the median was 65.00% per year.

Competitive Comparison of Viva Biotech Holdings's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Viva Biotech Holdings's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viva Biotech Holdings's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Viva Biotech Holdings's 3-Year Revenue Growth Rate falls into.

Save Embed

;

Save Embed

;

Viva Biotech Holdings 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Viva Biotech Holdings (OTCPK:VBIZF) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Viva Biotech Holdings 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Viva Biotech Holdings's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Viva Biotech Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viva Biotech Holdings (OTCPK:VBIZF) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

01873:Hong Kong VB0:Germany

Address

735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318

Website

https://www.vivabiotech.com

Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation (CDMO) and commercialisation services segment include contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates, and formulations. Geographically, the company generates a majority of its revenue from the United States of America, and the rest from the European Union, Chinese Mainland, Africa, and other regions.